"
The New Molecular Entity Evolocumab, One Kind of PCSK9 Inhibitor, Reduce Plasma Small Size LDL-Cholesterol Levels by Using a New Standardized Method of Measuring LDL Size"
written by Ikuo Inoue, Ryo Kubota, Shohan Yanagi, Masumi Akita, Takanari Nakano, Shigehiro Katayama, Akira Shimada, Mistuhiko Noda,
published by
Open Journal of Molecular and Integrative Physiology,
Vol.7 No.1, 2017
has been cited by the following article(s):
|
[1]
|
Relative increase in production ratio of small dense low-density lipoprotein in acute coronary syndrome with high coronary plaque burden: an ex-vivo analysis
Heart and Vessels,
2025
DOI:10.1007/s00380-024-02440-3
|
|
|
|
|
[2]
|
Relative increase in production ratio of small dense low-density lipoprotein in acute coronary syndrome with high coronary plaque burden: an ex-vivo analysis
Heart and Vessels,
2024
DOI:10.1007/s00380-024-02440-3
|
|
|
|
|
[3]
|
Small dense low-density lipoprotein-lowering agents
Biological Chemistry,
2020
DOI:10.1515/hsz-2019-0426
|
|
|
|
|
[4]
|
Small dense low-density lipoprotein-lowering agents
Biological Chemistry,
2020
DOI:10.1515/hsz-2019-0426
|
|
|
|
|
[5]
|
The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
npj Aging and Mechanisms of Disease,
2018
DOI:10.1038/s41514-018-0026-2
|
|
|
|
|
[6]
|
The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
npj Aging and Mechanisms of Disease,
2018
DOI:10.1038/s41514-018-0026-2
|
|
|
|
|
[7]
|
The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
npj Aging and Mechanisms of Disease,
2018
DOI:10.1038/s41514-018-0026-2
|
|
|
|